~~<i id='BA4AFBA271'><strike id='BA4AFBA271'><tt id='BA4AFBA271'><pre id='BA4AFBA271'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

leisure time

author：comprehensive 2025-09-06 04:41:19 - browse：7747

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Mitch McConnell episode has important public health takeaway

hotspot

focus

hotspot

focus

hotspot

AlastairGrant/APSengChenghasbeenworkingingenetherapyfornearlyaslongasgenetherapyhasbeenafield.Asayou

WSS

Complete sequence of Y chromosome published for first time

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

What to expect as Trump is arraigned on his Jan 6. indictment

Wildfire pollution widens asthma inequities on Long Island

Radiation, mainstay of cancer treatment, begins a fade

Drug firms test therapies to halt Alzheimer’s before symptoms arise

explore

leisure time

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

What do new weight loss drugs mean for bariatric surgery?

Hollywood unions extend contract negotiations for actors

How to make AI work for medicine

Cancer drug shortages should be causing more outrage

Vertex non

New air purifier tech could be key to improving indoor air quality

As pharma fights Medicare drug negotiation, hospitals, docs silent

Jerome Adams on the need for new antivirals for Covid

Trump indictment: Who are the 'co

focus

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

What the airline industry can learn from medicine

Winners, losers from Medicare’s list of drugs subject to price talks

As pharma fights Medicare drug negotiation, hospitals, docs silent

Neuroscience startup Neumora files for IPO

5 important ways Henrietta Lacks changed medical science

hotspot

hotspot

focus

hotspot